Caitong International Asset Management Co. Ltd Raises Position in Prestige Consumer Healthcare Inc. $PBH

Caitong International Asset Management Co. Ltd grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 312.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 330 shares of the company’s stock after acquiring an additional 250 shares during the period. Caitong International Asset Management Co. Ltd’s holdings in Prestige Consumer Healthcare were worth $26,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in PBH. GAMMA Investing LLC boosted its holdings in shares of Prestige Consumer Healthcare by 35.9% in the first quarter. GAMMA Investing LLC now owns 1,879 shares of the company’s stock valued at $162,000 after acquiring an additional 496 shares in the last quarter. KBC Group NV boosted its holdings in shares of Prestige Consumer Healthcare by 7.4% in the first quarter. KBC Group NV now owns 2,199 shares of the company’s stock valued at $189,000 after acquiring an additional 151 shares in the last quarter. Meritage Portfolio Management boosted its holdings in shares of Prestige Consumer Healthcare by 6.8% in the first quarter. Meritage Portfolio Management now owns 13,702 shares of the company’s stock valued at $1,178,000 after acquiring an additional 876 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 3.2% in the first quarter. Principal Financial Group Inc. now owns 264,817 shares of the company’s stock valued at $22,766,000 after acquiring an additional 8,291 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new stake in shares of Prestige Consumer Healthcare in the first quarter valued at about $361,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $62.46 on Tuesday. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The stock has a market cap of $3.07 billion, a P/E ratio of 14.66, a PEG ratio of 1.97 and a beta of 0.44. The company has a 50-day moving average of $64.01 and a two-hundred day moving average of $74.44. Prestige Consumer Healthcare Inc. has a 12-month low of $60.15 and a 12-month high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The business had revenue of $249.53 million for the quarter, compared to analyst estimates of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business’s revenue was down 6.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on PBH. Wall Street Zen downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a report on Monday. Oppenheimer decreased their price objective on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a report on Tuesday, October 21st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus target price of $87.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.